Ophthalmic toxicity systemic effects

Various colloidal systems have been studied for use as potential ophthalmic delivery systems, including liposomes and nanoparticles. Liposomes are bioerodible and biocompatible systems consisting of microscopic vesicles composed of lipid bilayers surrounding aqueous compartments. Liposomes have demonstrated prolonged drug effect at the site of action but with reduced toxicity. Ophthalmic studies have included topical, subconjunctival, and intravitreal administration, but no commercial preparations are currently available for ophthalmic use. 

British antilewisite (BAL) or dimercaprol was developed as an antidote for lewisite. It is used in medicine as a chelating agent for heavy metals. Although BAL can cause toxicity itself, evidence suggests that BAL in oil administered intramuscularly will reduce the systemic effects of lewisite. BAL skin and ophthalmic ointment decrease the severity of skin and eye lesions when applied immediately after early decontamination, but neither of these ointments is currently manufactured. 

Sodium sulfacetamide ophthalmic solution or ointment is effective treatment for bacterial conjunctivitis and as adjunctive therapy for trachoma. Mafenide acetate is used topically to prevent bacterial colonization and infection of burn wounds. Mafenide is absorbed from burn sites, and systemic levels are produced. The drug and its primary metabolite also inhibit carbonic anhydrase and can cause metabolic acidosis, a side effect that limits its usefulness. Silver sulfadiazine is a much less toxic topical sulfonamide and is preferred to mafenide for prevention of infection of burn wounds. 

All ophthalmic medications are potentially absorbed into the systemic circulation (Figure 63-3), so undesirable systemic side effects may occur, as well as potential local toxic effects due to hypersensitivity reactions or to direct toxic effects on the cornea, conjunctiva, periocular skin, and nasal mucosa. Eyedrops and contact lens solutions commonly contain preservatives such as ben-zalkonium chloride, chlorobutanol, and chelating agents for their antimicrobial effectiveness. In particular, benzalkonium chloride may cause a punctate keratopathy or toxic ulcerative keratopathy. 

Trifluridine 15-30 mg/kg IV Reversible bone marrow toxicity reported atter 3-5 courses of IV treatment. Systemic absorption is negligible after ophthalmic instillation. Ingestion of contents ot one bottle (7.5 mL, 75 mg) unlikely to cause any adverse effects. 

Ophthalmic diseases are most commonly treated by topical instillation of eye drops. These formulations evidence limitations like poor stability and efficacy, reduced cor-neal/scleral permeability, systemic toxicity and lack of compUance [2]. In this sense, the development of effective therapies for visual disorders is of high priority [1], which makes the field of ocular delivery one of the most interesting and challenging areas for pharmaceutical scientists [3]. There has been significant research directed towards the development of new systems for controlled drug delivery in ophthalmology such... 

Ocular toxicity and systemic adverse effects of 0.3% ofloxacin ophthalmic solution (0.3%OFLX) which was administered 3 times daily for one year were studied in dogs. 

It is concluded from these results that one year application of 0.3%OFLX ophthalmic solution to dogs causes neither ocular toxicity nor systemic adverse effect. 

In the present study, we examined ocular toxicity of ofloxacin ophthalmic solution (3 times daily for one year application) in beagle dogs with pigmented eyes. In order to investigate the effects of melanin-bound ofloxacin on retinal function and the effect of ofloxacin on central nerve system, electroretinogram (ERG) was recorded and behavior of dogs was observed during test periods. 

---